loading
Crinetics Pharmaceuticals Inc stock is traded at $53.58, with a volume of 454.96K. It is down -1.83% in the last 24 hours and down -9.09% over the past month. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
See More
Previous Close:
$54.72
Open:
$54.35
24h Volume:
454.96K
Relative Volume:
0.68
Market Cap:
$5.05B
Revenue:
$4.72M
Net Income/Loss:
$-258.54M
P/E Ratio:
-15.71
EPS:
-3.41
Net Cash Flow:
$-185.05M
1W Performance:
-10.48%
1M Performance:
-9.09%
6M Performance:
+4.51%
1Y Performance:
+79.13%
1-Day Range:
Value
$52.84
$55.05
1-Week Range:
Value
$52.84
$62.53
52-Week Range:
Value
$29.23
$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name
Name
Crinetics Pharmaceuticals Inc
Name
Phone
858-450-6464
Name
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Name
Employee
210
Name
Twitter
@Crinetics
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
CRNX's Discussions on Twitter

Compare CRNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CRNX 53.74 5.05B 4.72M -258.54M -185.05M -3.41
VRTX 467.45 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.74 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.72 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.44 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.56 24.08B 3.30B -501.07M 1.03B 11.54

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-06-24 Initiated Citigroup Buy
Jan-16-24 Initiated Morgan Stanley Overweight
Dec-21-23 Initiated Jefferies Hold
Nov-20-23 Resumed JP Morgan Overweight
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-31-23 Initiated Oppenheimer Outperform
Apr-24-23 Initiated Piper Sandler Overweight
Mar-30-23 Initiated Robert W. Baird Outperform
Nov-30-21 Initiated JMP Securities Mkt Outperform
Nov-23-21 Initiated Evercore ISI Outperform
Jun-18-21 Upgrade JP Morgan Neutral → Overweight
Dec-23-19 Initiated ROTH Capital Buy
Feb-14-19 Initiated H.C. Wainwright Buy
Aug-13-18 Initiated JP Morgan Neutral
Aug-13-18 Initiated Leerink Partners Outperform
Aug-13-18 Initiated Piper Jaffray Overweight
View All

Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News

pulisher
02:36 AM

Leerink Partnrs Has Strong Forecast for CRNX FY2024 Earnings - MarketBeat

02:36 AM
pulisher
Nov 16, 2024

Learn to Evaluate (CRNX) using the Charts - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

FY2024 Earnings Forecast for CRNX Issued By Lifesci Capital - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

HC Wainwright Has Bearish Estimate for CRNX FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Steven Cohen's Recent Transaction in Crinetics Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Evercore 7th Annual HealthCONx Conference - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Crinetics Pharmaceuticals : 2024 Cantor Global Healthcare Conference - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - The Manila Times

Nov 15, 2024
pulisher
Nov 15, 2024

Crinetics Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | CRNX Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

EcoR1 Capital, LLC Increases Stake in Crinetics Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Has Pessimistic View of CRNX FY2024 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week High Following Analyst Upgrade - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Crinetics Unveils Breakthrough Cancer Drug Platform, Reports Positive Phase 2 Trial Results | CRNX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highl - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail

Nov 12, 2024
pulisher
Nov 12, 2024

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Crinetics Pharmaceuticals to Showcase Pipeline Advancements - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Crinetics Pharmaceuticals, Inc. Announces Additional Data from the 2 Study of Its Investigational Drug Atumelnant in Cah Is Anticipated by Early 2025 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Crinetics' Breakthrough: Phase 2 Trial Success & Novel NET Treatment Pipeline Advances | CRNX Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Acromegaly Market Forecasted to Surge in Coming Years, - openPR

Nov 12, 2024
pulisher
Nov 12, 2024

CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Crinetics Grants 99,500 Stock Options to New Hires at $60.69, Expanding Team | CRNX Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Lisanti Capital Growth LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Crinetics Pharmaceuticals (CRNX) to Release Earnings on Tuesday - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Fiera Capital Corp Sells 14,334 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP Reduces Stake in Crinetics Pharm - GuruFocus.com

Nov 08, 2024
pulisher
Nov 07, 2024

CRNX (Crinetics Pharmaceuticals) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 07, 2024
pulisher
Nov 05, 2024

(CRNX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 05, 2024

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by abrdn plc - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Crinetics Pharmace - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR

Nov 04, 2024
pulisher
Oct 30, 2024

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week - Yahoo Finance

Oct 30, 2024
pulisher
Oct 24, 2024

Moody Aldrich Partners LLC Sells 11,053 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year HighHere's What Happened - MarketBeat

Oct 22, 2024
pulisher
Oct 20, 2024

Analysts Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $68.55 - MarketBeat

Oct 20, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

Crinetics Pharmaceuticals’ $500 Million Common Stock Offering - Global Legal Chronicle

Oct 17, 2024
pulisher
Oct 16, 2024

Crinetics Pharmaceuticals outlines executive transition By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

Crinetics Pharmaceuticals outlines executive transition - Investing.com India

Oct 16, 2024
pulisher
Oct 16, 2024

Crinetics Pharmaceuticals Inc’s results are impressive - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 12-Month HighWhat's Next? - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Crinetics Pharmaceuticals Inc (CRNX) Stock: A Year of Market Movement, Down and Up - The InvestChronicle

Oct 16, 2024

Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Pizzuti Dana
Chief Med and Dev Officer
Oct 03 '24
Sale
54.63
14,375
785,306
28,507
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):